<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The coexistence of <z:hpo ids='HP_0002870'>obstructive sleep apnea</z:hpo> (OSA) and <z:hpo ids='HP_0010536'>central sleep apnea</z:hpo> (CSA) and Cheyne-Stokes respiration (CSR) is common in patients with <z:hpo ids='HP_0001635'>heart failure</z:hpo> (HF) </plain></SENT>
<SENT sid="1" pm="."><plain>While CPAP improves CSA/CSR by about 50%, maximal suppression is crucial in improving clinical outcomes </plain></SENT>
<SENT sid="2" pm="."><plain>Auto-servoventilation (ASV) effectively suppresses CSA/CSR in HF, but few trials have been performed in patients with coexisting OSA and CSA/CSR </plain></SENT>
<SENT sid="3" pm="."><plain>Our objective was to evaluate a randomized, controlled trial to compare the efficacy of ASV and CPAP in reducing breathing disturbances and improving cardiac parameters in patients with HF and coexisting <z:e sem="disease" ids="C0037315" disease_type="Disease or Syndrome" abbrv="">sleep-disordered breathing</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Both modes were delivered using the BiPAP autoSV (Philips Respironics) over a 12-month period </plain></SENT>
<SENT sid="5" pm="."><plain>Seventy patients (63 men, 66.3 ± 9.1 y, BMI 31.3 ± 6.0 kg/m(2)) had coexisting OSA and CSA/CSR, arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e>, or <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and clinical signs of <z:hpo ids='HP_0001635'>heart failure</z:hpo> New York Heart Association classes II-III </plain></SENT>
<SENT sid="6" pm="."><plain>Polysomnography, brain natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (BNP), spiroergometry, and echocardiography were performed at baseline and after 3 and 12 months of treatment </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Both modes of therapy significantly improved respiratory disturbances, oxygen desaturations, and arousals over the study period </plain></SENT>
<SENT sid="8" pm="."><plain>ASV reduced the <z:hpo ids='HP_0002871'>central apnea</z:hpo> <z:mp ids='MP_0001956'>hypopnea</z:mp> index (baseline CPAP, 21.8 ± 11.7; ASV, 23.1 ± 13.2; 12 months CPAP, 10.7 ± 8.7; ASV, 6.1 ± 7.8, P &lt; .05) and BNP levels (baseline CPAP, 686.7 ± 978.7 ng/mL; ASV, 537.3 ± 891.8; 12 months CPAP, 847.3 ± 1848.1; ASV, 230.4 ± 297.4; P &lt; .05) significantly more effectively as compared with CPAP </plain></SENT>
<SENT sid="9" pm="."><plain>There were no relevant differences in exercise performance and echocardiographic parameters between the groups </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: ASV improved CSA/CSR and BNP over a 12-month period more effectively than CPAP </plain></SENT>
</text></document>